Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda meets survival challenge in NSCLC
Merck &Co’s grip on the first-line non-small cell lung cancer (NSCLC) immunotherapy market seems set to tighten, after its PD-1 inhibitor Keytruda halved the risk of death ... The company is now preparing to file the data with regulators around with
Latest news
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
Sutent sales slipped 1% last year to just over $1bn but could suffer as Opdivo and other cancer immunotherapies get approved in front-line RCC, despite Pfizer claiming FDA approval of
-
Merck’s Keytruda scores in frontline lung cancer yet again
handed the first-line NSCLC immunotherapy market to Merck’s drug.
-
Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal
It is also something of a late entrant to the cancer immunotherapy category, but has started to build a presence in recent years, both via in-house R&D and also ... For instance, it licensed CureVac ’s cancer vaccine CV9202 in 2014, formed a
-
Incyte/Merck trial failure bodes ill for IDO class
Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted
-
Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug
EpiDestiny is hanging on to rights for the drug as a cancer immunotherapy for p53-mediated diseases such as acute promyelocytic leukaemia (APL), and has said it expects to start phase
More from news
Approximately 57 fully matching, plus 314 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell
-
The good, the bad and the ugly
2018 looks set to be an interesting year - coloured by the prospect of M&A, patent expiry and pricing challenges, but also invigorated by exciting advances in immunotherapy and oncology and
-
IQVIA: The High IQ Approach of Human Data Science
Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?
-
IQVIA: The High IQ Approach of Human Data Science
Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?
-
Deal Watch March 2017
BioLineRx. Acquisition. Portfolio, including AGI-134, synthetic alpha-GaI immunotherapy for solid tumours.
More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.
Latest appointments
-
Zelluna Immunotherapy appoints chief technology officer
Zelluna Immunotherapy appoints chief technology officer. Arjan Roozen will consolidate the biotech’s manufacturing strategy. ... Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
immunotherapy category.
-
Christian Pangratz to head up Sterna Biologicals
Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior
-
Dave Lemus joins Proteros as an executive board member
Prior to his new roles, Lemus was chief operating officer and chief financial officer of Medigene, assisting in its transformation into an immunotherapy-based company through the establishment of strategic partnerships.
More from appointments
Approximately 2 fully matching, plus 41 partially matching documents found.
Latest from PMHub
-
Focus on immunotherapies: special magazine from Blue Latitude Health
In this supplementary issue, we’ re taking a special look at immunotherapies, and more specifically, the growing buzz around “ immuno-oncology” therapies. ... What new immunotherapies in oncology mean for cancer patients and the doctors who would
-
Immunotherapy in oncology
What is Immunotherapy? Immunotherapy, is a type of cancer treatment designed to boost the body’ s natural defences to fight the cancer. ... With immunotherapies, even patients with stable disease have experienced significant survival benefit while
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships. ... The first generation of agents has shown some interesting results, while also highlighting the limits of immunotherapies in oncology.
-
A stumble, but not a fall – what’s next for Opdivo?
Bristol-Myers Squibb's (BMS, $BMY) immunotherapy wonder drug Opdivo (nivolumab) was poised for lasting success.
-
Perspective on biotech
Find out about:. The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.
More from PMHub
Approximately 9 fully matching, plus 9 partially matching documents found.
Featured jobs
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
-
Senior Medical Writer
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Programme Executive
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Scientific Director
-
Great salary and bebefits
Subscribe to our email news alerts
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
